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Clearance of pentosidine, an advanced glycation end product, by
different modalities of renal replacement therapy. We recently demon-
strated that pentosidine, an advanced glycation end product, accumulates
markedly as albumin-linked form (Paib) and in free-form (Pfre,) in the
plasma of patients with end-stage renal failure. The present study was
undertaken to examine the clearance of ajh and 1fre by different
modalities of renal replacement therapy, that is, hemodialysis (HD),
continuous ambulatoiy peritoneal dialysis (CAPD), and renal transplan-
tation. HD cleared frce (9.4 4.3 nmol/kg/HD) but not Paib, by diffusion
but not by membrane adsorption, whereas CAPD cleared both P,
(4.03 2.01 nmol/kg/day) and frcc (2.43 1.24 nmol/kg/day). Plasma
total pentosidine levels were significantly (P < 0.05) lower in CAPD
(0.97 0.41 nmol/ml) than in HD (1.19 0.41 nmol/ml), as the result of
a lower serum albumin level in the former patients. Indeed, P15 expressed
per mg albumin was virtually identical in HD and CAPD. By contrast, frcc
was significantly lower in CAPD than in HD. Ih levels were significantly
correlated with plasma free levels in both HD and CAPD patients, but not
in the CAPD dialysate. Pentosidine transport across the peritoneum
occurs mainly by diffusion, both as a!h and Pf,. Interestingly, peritoneal
1aIh clearance (0.17 0.07 mI/mm) significantly (P < 0.00001) exceeded
albumin clearance (0.11 0.05 mI/mm). Ih levels being significantly
higher (P < 0.0005) in the peritoneal fluid (36.28 18.55 pmol/mg) than
in the serum (27.12 11.71 pmol/mg), thus raises the possibility of a
facilitated diffusion of or an active transport mechanism for protein-
linked pentosidine into the peritoneal cavity. After renal transplantation,
plasma 1free fell rapidly, remained barely detectable after one month, and
returned to normal at six months. By contrast, P1,, fell more slowly and
remained significantly above normal at six months, but returned eventually
to normal levels. These findings demonstrate that: (1) both HD and
CAPD remove frco (2) the peritoneal clearance of aIh might contribute
to the lower level of plasma pentosidine in CAPD than in HD patients;
and (3) renal transplantation is the best therapeutic modality to normalize
both Ib and fr levels.
Advanced glycation end products (AGEs) are formed, over the
months, by a non-enzymatic reaction between aldoses and pro-
teins, known as the Maillard reaction [1, 2]. They Constitute a
heterogeneous class of structures that are brown in color, fluo-
resce, and form cross-links. AGEs levels in plasma proteins and
skin collagens increase with age and at an accelerated rate in
patients with diabetes mellitus and end-stage renal failure [3—5].
AGE-modified proteins are thought to play a role in normal tissue
remodeling, that is, the removal and replacement of senescent
extracellular matrix components. Their accumulation might lead
to tissue damage through a variety of mechanisms: an alteration of
the structure and function of tissue proteins [1]; the stimulation of
cellular responses [6—10] via receptors specific for AGE-modified
proteins [11—13]; or the generation of reactive oxygen intennediates
[14]. They have thus been implicated in the pathogenesis of athero-
sclerosis [6, 7, 13], diabetic nephropathy [15, 16], dialysis-related
amyloidosis [8—10, 17—19], and Alzheimer's disease [20, 21].
Pentosidine, a fluorescent cross-link formed during glycoxida-
tion of Amadori product [22], has been used as a marker for
AGEs [14]. In diabetic patients, it has been identified in skin
collagen [22—24], glomerular basement membrane [22, 25] and
plasma proteins of diabetic patients [22, 26, 271. Pentosidine level
in the skin is correlated with the severity of vascular complications
[28, 29]. In patients with end-stage renal failure treated by
hemodialysis (HD), pentosidine levels are dramatically raised in
plasma proteins [26, 27, 30, 31], /32-microglobulin amyloid depos-
its [19] and skin collagens [26, 27, 30], irrespective of the presence
or absence of diabetes.
We recently demonstrated that in the plasma, protein-linked
pentosidine is almost exclusively linked to albumin. In addition, a
small fraction of plasma pentosidine exists in a free-form, which
was undetectable in either normal or diabetic patients with
normal renal function. Accumulation of free pentosidine was
further shown to be due to decreased glomerular filtration [31]. By
contrast, accumulation of albumin-linked pentosidine could not
he explained by either increased generation due to high glucose
levels or poor removal through the glomerulus [311, suggesting
that an unknown pentosidine precursor(s) or catalyst(s) accumu-
late in renal failure.
The present study was undertaken to examine how plasma
pentosidine (both albumin-linked and free-form) is cleared by
different modalities of renal replacement therapy, that is, HD,
continuous ambulatory peritoneal dialysis (CAPD), and renal
transplantation.
Methods
Samples
Fresh heparinized plasma samples were obtained with informed
consent from normal subjects (Group I in Table 1), non-diabetic
HD patients (Group II), non-diabetic CAPD patients (Group Ill),
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Table 1. Profile of subjects examined in this study
Group
No. of
subjects Male
Sex Plasma total
Age pentosidine
Female years nmol/ml pmo
Plasma total
pentosidine
1/mg of total protein
I Normal subjects 20 14 6 58.20 5.93 0.11 0.02 1.57 0.23
II Hemodialysis patients
Pre-HD 29 11 18 57.66 9.24 1.19 0.41°" 17.53 5.64""
Post-HD — — — — 1.31 0.50°'" 17.15 581°"
111 Peritoneal dialysis patients 30 18 12 50.54 9.18 0.97 0.41° 14.10 6.04°
-
Table 1. Continued
Group
Plasma aIb
pmol/mg of
albumin
Plasma protein Plasma albumin
Plasma frec
pmol/ml mg/mI
Duration of
dialysis
years
I Normal subjects 2.50 0.36 ND 70.91 2.09 44.66 1.32°
II Hemodialysis patients
Pre-HD 26.64 9.15° 53.97 13.11° 67.64 7.28 42.58 3.92c 12.04 7.86
Post-HD 27.16 9.86° 12.09 4.85° 75.34 6.98 47.67 6.16°
III Peritoneal dialysis patients 27.12 11.71' 24.80 12.29 69.50 3.45 35.22 3.07 2.81 2.17
a P < 0.0001 vs. Normal subjects
"P < 0.05 vs. Peritoneal dialysis patients
cp < 0.0001 vs. Peritoneal dialysis patients
and non-diabetic patients who have undergone successful renal
transplantation without rejection (N = 7). An additional group of
long-term transplanted patients (N = 12) with a successful graft
(serum creatinine levels, below 1.0 mg/dl) was investigated. The
CAPD dialysate was also obtained from Group III patients. HD
was performed with a cuprophane dialyzer (membrane area 1.8 to
2.0 m2) and dialysate containing 30 mmol/liter of bicarbonate and
8 mmol!liter of acetate. CAPD was performed by four exchanges
daily (3 in the daytime and 1 overnight) with 3 liters of dialysate
containing either 1.36% or 2.27% glucose (Baxter Healthcare,
Round Lake, IL, USA). The albumin concentration in the plasma
and dialysate was determined antigenically using anti-human
serum albumin antibody (Behringwerke AG Diagnostica, Mar-
burg, Germany) on a nephelometer analyzer (Behringwerke AG
Diagnostica). The protein concentration was determined using
Bio-Rad protein assay reagents (Richmond, CA, USA) with
human serum albumin as a standard. Separation of proteins in the
plasma or dialysate was performed by gel filtration on a Sephacryl
S-200 column (5.0 x 67 cm; Pharmacia, Uppsala, Sweden).
Pentosidine measurement by HPLC assay
For quantitation of total pentosidine in the plasma, CAPD
dialysate, or their fractions, the sample was lyophilized, hydro-
lyzed by 100 1.d of 6 N HC1 for 16 hours at 110°C under nitrogen,
followed by neutralization with 100 ,tLl of 5 N NaOH and 200 ,tl of
0.5 M phosphate buffer (pH 7.4), then filtered through a 0.5
tim-pore filter, and diluted with PBS. For quantitation of free-
form pentosidine (Pfre), the sample was mixed with an equal
volume of 10% TCA and centrifuged at 5000 X g for 10 minutes.
The supernatant was filtered through a 0.5 m filter and diluted
with distilled water. Pentosidine in these specimens was analyzed
by reverse-phase HPLC according to our previous method [311.
Briefly, a 50 d solution of acid hydrolysate of plasma or dialysate
(corresponding to 25 g of proteins) or diluted protein-free
plasma or dialysate (corresponding to 6.25 .tl of plasma) was
injected into an HPLC system and separated on a C18 reverse-
phase column (Waters, Tokyo, Japan). The effluent was moni-
tored using a fluorescence detector (RF-1OA; Shimadzu) and an
excitation-emission wavelength of 335/385 nm. Synthetic pentosi-
dine was used to obtain a standard curve. The substance in the
specimens, detected at the same retention time as authentic
pentosidine, was confirmed as pentosidine by fast atom bombard-
ment-mass spectrometry. For comparison purposes, total pento-
sidine is expressed both as pmol per ml of plasma and pmol per
mg of total protein. Since albumin is the only protein linking
pentosidine in the plasma (Results), the albumin-linked pentosi-
dine (Paib) level was calculated: aIb (pmol/mg of albumin) =
[total pentosidine (pmol/ml) free (pmol/ml)]/albumin (mg/mi).
aIb and free levels were expressed as pmol per mg of albumin
and pmol per ml of plasma or dialysate, respectively. Limits of
detection were 0.05 pmol/mg for 'aIh and 4 pmol/ml for free
Statistical analysis
Data are expressed as means SD. Student t-test was used for
a statistical evaluation of significant difference between the two
groups. Correlation was assessed by linear regression analysis.
Results
Clearance of plasma free by HD
Gel filtration of plasma proteins from HD patients (pre-
dialysis) showed that pentosidine existed as albumin-linked (Pa,,,)
and free-form (Ptree) in the plasma (Fig. 1A). HPLC assay
revealed that the plasma level in HD patients (pre-dialysis)
was significantly higher (P < 0.0001) than that in normal subjects
(26.64 9.15 pmol/mg vs. 2.50 0.36 pmol/mg; Fig. 2B), and that
frce accumulated in the plasma of the former (53.97 13.11
pmol/ml) hut was undetectable in the latter patients (Fig. 2C).
Total pentosidine level expressed as pmol/ml rises during
dialysis as a result of hemoconcentration (Fig. 2A); indeed, it
remains constant once expressed as nmol/mg of total protein
(Table 1). More specifically, pre- and post-dialysis levels of aIb
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Fig. 1. Representative profiles of pentosidine level in the fractions of plasma
from pre-dialsis 1-TI) patients (A) and CAPD patients (B), and in the
fractions of peritoneal dialysate from CAPD patients (C). Separation of
proteins in the specimens was performed by gel filtration on a Sephacryl
S-200 column chromatography. The proteins in each fraction were de-
tected by their absorbance at 280 nm. The pentosidine content in acid
hydrolysate of each fraction was measured by HPLC assay and expressed
as percentage of total pentosidine. Symbols are: (•) pentosidine level; (0)
absorbance at 280 nm. a, IgG (150 kDa); b, albumin (67 kDa). P11, and
1trc are indicated by arrows and arrowheads, respectively.
are not significantly different: 26.64 9.15 pmol/mg versus
27.16 9.86 pmol/mg (Fig. 2B). By contrast, the post-dialysis level
of (12.09 4.85 pmol/ml) is significantly lower (P < 0.000 1)
than the pre-dialysis level (53.97 13.11 pmol/ml; Fig. 2C). Thus,
HD failed to modify plasma alh but lowered fr by more than
125
f l/ l
0
[PreHD
L Post-H
Ill
Fig. 2. Plasma total pentosidine (A), albumin-linkedpentosidine (P,5) (B),
andfree pentosidine (P1) levels (C) in normal subjects (Group I, N = 20),
HD patients (pre-dialysis, Group 11, N = 29), HD patients (post-dialysis),
and CA PD patients (Group 111, N 30). The total pentosidine level in acid
hydrolysate of plasma and the frec level in the protein-free plasma were
determined by HPLC assay (Methods). alj. (pmol/mg of albumin) = [total
pentosidine (pmol/ml) — frc (pmol/ml)1/albumin (mg/mI). Data are
expressed as means SD. 'P < 0.0001 vs. normal subjects and 5P < 0.05
vs. CAPD patients. Abbreviations are: NS, not significant; ND, not
detected.
75%, an observation well accounted for by the fact that aIh (67
kDa), in contrast with 1'fr,,,, (0.37 kDa), is not filtered through the
dialysis membrane.
As shown in Figure 3, free levels were lowered by approxi-
mately 82% at the end of the HD session and returned progres-
sively towards the pre-dialysis value. An average frcc removal per
session of 436 213 nmol may be calculated on the assumption
that frc,, is distributed through the extracellular volume (mean
body weight 48.9 kg pre- and 46.6 kg post-dialysis, that is, 9.4 43
nmollkg). If it is further assumed that frcc removal per HD
session is equivalent to the amount generated between two
sessions, Pfr, generation averages 5.08 2.34 nmol/kg!day.
Synthesized pentosidine did not bind to cuprophane membrane
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Pentosidine also existed as 1alh and free in the plasma of
CAPD patients (Fig. 1B). The plasma a1b (27.12 11.71
pmol/mg) and 1free (24.80 12.29 pmol!ml) levels were signifi-
cantly higher (P < 0.0001) than in normal subjects (Fig. 2B).
Plasma total pentosidine levels expressed as either nmol/ml or
pmol/mg of total protein were significantly lower (P < 0.05) in
CAPD than in HD patients (0.97 0.41 nmol/ml vs. 1.19 0.41
nmol/ml or 14.10 6.04 pmol/mg vs. 17.53 5.64 pmol/mg; Table
1). However, plasma ajb levels did not differ between HD and
CAPD patients (Fig. 2A). This discrepancy is due to the signifi-
cantly (P < 0.0001) lower albumin levels in CAPD (35.22 3.07
mglml) than in HD patients (42.58 3.92 mglml) despite similar
protein levels.
The 'free level is significantly (P < 0.0001) lower in CAPD
(24.80 12.29 pmol/ml) than in HD patients (pre-dialysis,
53.97 13.11 pmol/ml; Fig. 2C) and also lower than the inte-
grated values of the plasma free in HD patients. Gel filtration of
the peritoneal dialysate confirms the presence of both aJh and
free (Fig. IC). Plasma 'free continuously accumulates into the
peritoneal dialysate during the four-hour dwell time without
reaching equilibrium (Fig. 4). Hence, in CAPD patients, plasma
pentosidine is cleared as both Paib and free' Daily removal
calculated from the dialysate fluid content amounts to 4.03 2.01
nmol/kg for alb and 2.43 1.24 nmol/kg for 1trcc
There was a significant correlation between levels of plasma
aIh and free in both HD patients (P < 0.01) and CAPD patients
(P < 0.001; Fig. 5). However, there was no correlation between
peritoneal aIh and frce in CAPD patients (Fig. 6), reflecting the
different diffusibility of aIh and free'
Pentosidine transport across the peritoneal membrane occurs
largely through diffusion, as a1b and frec clearance roughly
depend upon their molecular weight (Fig. 7). Interestingly, calcu-
lated peritoneal clearance of aJh (0.17 0.07 mI/mm) was slightly
but significantly higher (P <0.00001) than that of albumin (0.11
0.05 mI/mm; Fig. 8A). Peritoneal aIb levels (36.28 18.55
pmol/mg) were significantly higher (P < 0.0005) than plasma alb
levels in CAPD patients (27.12 11.71 pmol/mg; Fig. 8B). To
know whether the higher alh content in the peritoneal cavity was
due to intraperitoneal pentosidine formation with glucose, human
serum albumin was incubated for 8 hours at 37°C in vitro in
dialysate containing 2.27% glucose. Pentosidine content remained
below the detection level (0.05 pmol/mg), a finding taken to
indicate that the intraperitoneal 'aIb originated from the plasma.
Plasma /b and Pf, levels after renal transplantation
After renal transplantation, plasma free fell rapidly by 90%
within a week, remained slightly above normal after one month,
and had become undetectable six months after transplantation
(Fig. 9A), suggesting a continuous release of free pentosidine
from a tissue reservoir. By contrast, plasma aIb fell by 50% within
a week, by 70% after one month and by 80% after six months, alh
being still significantly above normal (3.67 vs. 2.50 pmol/mg of
albumin, P < 0,05; Fig. 9B). Plasma pentosidine levels measured
in transplanted non-diabetic patients with a long-term successful
graft (N 12; serum creatinine levels, below 1.0 mg/dl; mean graft
duration 6.17 years) were normal; plasma free was undetectable
and the jb levels (2.50 0.74 pmol/mg) were within the normal
range.
Discussion
Our observations confirm the accumulation of pentosidine in
the serum of patients undergoing chronic hemo- or peritoneal
dialysis. The separate analysis of the two forms of pentosidine,
that is, the serum albumin-linked (95%) and free-form (5%),
80
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Fig. 3. Kinetics of Pfr after HD. Heparinized blood was taken at intervals
after HD from HD patients (N = 4) and the Pfrec level was determined by
HPLC assay after removing plasma proteins.
upon incubation in vitro at 37°C overnight (data not shown), thus
suggesting that frce clearance occurs only by diffusion.
0 2 4
Time after bag exchange, hours
Fig. 4. Excretion of into the peritoneal dialysate. The peritoneal
dialysate was taken at intervals from CAPD patients (N = 4) and the
level was determined by HPLC assay after removing proteins.
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provides insights into the fate of pentosidine during renal replace-
ment therapy.
Total pentosidine levels are significantly higher in HD patients
than in CAPD patients, an observation in agreement with those of
Friedlander et al [30, 321. We demonstrate that this difference is
wholly accounted for by a higher level of serum albumin in HD
patients since ajh levels did not differ according to the dialysis
modality. Similarly, the rise in total pentosidine levels during a
HD session is accounted for by the concomitant, hemoconcentra-
tion related increase in serum albumin as demonstrated by
unchanged P, levels. levels are thus unaffected by dialysis
modality. The virtually identical levels of in HD and CAPD
patients argue strongly against the suggestion that lower pentosi-
dine levels in CAPD patients reflect a higher albumin turnover
when compared with HD patients [32].
By contrast, the fate of free pentosidine is markedly influenced
by the dialysis procedure. Plasma Pte falls by more than 80%
during a four-hour dialysis session with a 1.8 to 2.0 m2 cuprophanc
Molecular weight, Daltons
Fig. 7. Peritoneal clearance of pentosidine in CAPD patients. The levels of
creatinine, fre, 2-microglobulin, albumin, and ah in both plasma and
dialysate of CAPD patients (N = 30) were determined and the peritoneal
clearance of each substance was calculated. There was a significant
correlation between peritoneal clearance and molecular weight (P <
0.0001, r2 0.978). The equation of the line is y = —1.S8logx + 7.70.
membrane. Although it represents only 5% of total pentosidine, it
is the only pentosidine moiety cleared by dialysis. If it were
assumed that Pjç distributes only through the extracellular space,
then HD would clear around 9.4 nmol/kg per session, that is, 28
nmol/kg per week. fr is cleared through diffusion and ultrafil-
tration across, but not by adsorption on the cuprophane mem-
brane.
As may be anticipated, frcc diffuses through the peritoneal
membrane without reaching equilibrium after four hours, a
finding in agreement with a recent report of Friedlander et al [32].
The amount of frcc removed daily, calculated from dialysate bag
content, reaches approximately 2.4 nmol/kg. In addition, Plb also
diffuses with albumin within the peritoneal dialysate, resulting in
the daily removal of an additional 4.0 nmol/kg so that a total of 45
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nmol/kg of pentosidine is cleared weekly, an amount comparable
with that calculated for HD.
The pcritoncal clearance of the pentosidine moieties depends
mainly on their molecular weight, an observation suggesting that
it is diffusion dependant. More puzzling is the fact that Paib levels
are higher in the peritoneum than in the serum with the attendant
consequence that peritoneal P clearance exceeds albumin clear-
ance. Recently, Friedlander et al [321 also reported that perito-
neal protein-linked pentosidine clearance was larger than protein
clearance. We demonstrate that this phenomenon is mainly due to
enhanced aIh clearance.
The reasons of this discrepancy remain to be delineated. Our in
vii'o studies, as well as those of Friedlander et at [32] render the
intraperitoneal formation of P unlikely. The hypothesis that
highly glycated peritoneal tissue shed pentosidinc-rich proteins
[321 also appears unlikely in view of the fact that enhanced
protein-linked pentosidine clearance is limited to ajb Similarly,
the suggestion that glycation of the peritoneal membrane en-
hances its permeability to protein-linked pentosidine [321 is not
supported by the fact that the same discrepancy is observed in
normal subjects [32]. Further studies will be needed to assess the
possibility of an enhanced transport of protein-linked pentosidine
to the peritoneal cavity.
Whatever the mechanism involved, it is of interest that esti-
mated weekly removal of pentosidine is of the same order of
magnitude for both I-ID and CAPD, although the former relies
solely on frc clearance whereas the latter relies on both free and
alb clearance. The only resulting difference in plasma levels is a
lower plasma 1fr in CAPD than in HD patients. The clinical
relevance of these differences remains to be explored.
Pentosidine has been used as a marker for AGEs. We have
previously documented that frcc is not in dissociation equilibrium
with P1, [31]. This is further illustrated in the present study by the
lack of correlation between frcQ and ajb in the peritoneal
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Fig. 8. Comparison of the peritoneal clearance
between P,,11, and albumin (A), and comparison
of the levels between peritoneal and plasma
1h (B) in CAPD patients (N = 30). The levels
of albumin and P15 in both plasma and
dialysate of CAPD patients (N = 30) were
determined and the peritoneal clearance was
calculated. Data are expressed as means so.
Fig. 9. Plasma P1,, (A) and Pfr, (B) levels after
renal transplantation. Heparinized blood was
taken at intervals after renal transplantation
(N = 7) and the aIh and froc levels were
determined by HPLC assay.
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dialysate. Still, the possibility cannot be excluded that free
attaches slowly to proteins such as albumin by a concentration
dependent but irreversible process. The correlation between free
and alb observed both in CAPD and HD patients supports such
a possibility. Should this finding be extrapolated to other tissue
proteins such as skin collagen and 2-microglobulin amyloid,
plasma 'free levels might be one of the determinants of AGE
toxicity in uremic patients. The lack of correlation between skin or
peritoneal tissue pentosidine and plasma pentosidine levels [30]
does not refute this hypothesis, as only total and not plasma frce
was measured in this study. The validity of this speculation
remains, however, to be established.
Just as for other substances such as 2-microglobulin, whatever
their efficiency, dialysis techniques are unable to return pentosi-
dine levels to normal. By contrast, a successful graft returns
pentosidine levels towards but not necessarily to normal [33]. The
separate analysis of the pentosidine moieties provides further
insights into this phenomenon. We demonstrate that a successful
renal graft markedly reduces 'free levels by over 90% within one
week and by 100% within six months. The fall of plasma 1free is
delayed when compared with serum /32-microglobulin levels, but
values are back to normal within six months. This observation
suggests that significant amounts of frce are released from tissue
pentosidine stores probably as a result of protein catabolism. By
contrast, aIb remains abnormal up to six months, falling by 55%
after one week and by 70% after six months. In contrast with
Hricik et al's report [33], however, normal plasma pentosidine
levels were subsequently observed provided that graft function
was normal. The delayed clearance of jh might reflect partly a
slow decay of the protein and partly the persistence, for at least six
months after a successful transplantation, of metabolic conditions
promoting protein glycoxidation and thus the formation of alb
An influence of steroid treatment has been considered [3I•
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Appendix
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